TianYu Bio-Technology Co., Ltd. (SHA:603717)
China · Delayed Price · Currency is CNY 7.64
-0.04 (-0.52%)
Feb 3, 2026, 3:00 PM CST
TianYu Bio-Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 705.63 | 794.5 | 668.39 | 940.87 | 633.77 | 579.52 |
Other Revenue | 7 | 7 | 2.06 | 4.04 | 4.31 | 3.02 |
| 712.64 | 801.51 | 670.45 | 944.91 | 638.08 | 582.54 | |
Revenue Growth (YoY) | 1.56% | 19.55% | -29.05% | 48.09% | 9.53% | -30.43% |
Cost of Revenue | 696.7 | 732.8 | 990.07 | 859.29 | 588.92 | 520.65 |
Gross Profit | 15.93 | 68.71 | -319.62 | 85.62 | 49.16 | 61.89 |
Selling, General & Admin | 91.87 | 110 | 95.41 | 88.53 | 97.09 | 95.94 |
Research & Development | 16.09 | 11.29 | 13.91 | 26.38 | 10.37 | 12.92 |
Other Operating Expenses | 1.29 | 2.13 | 1.35 | 7.61 | 3.98 | 1.14 |
Operating Expenses | 99.94 | 145.43 | 114.76 | 354.67 | 283.67 | 145.16 |
Operating Income | -84.01 | -76.72 | -434.38 | -269.05 | -234.52 | -83.27 |
Interest Expense | -55.21 | -36.53 | -30.56 | -29.18 | -48.76 | -58.01 |
Interest & Investment Income | 31.39 | 29.9 | 11.67 | 19.71 | 37.52 | 18.84 |
Currency Exchange Gain (Loss) | 0.09 | 0.09 | 0 | - | - | - |
Other Non Operating Income (Expenses) | 3.81 | -1.27 | -0.51 | -31.16 | -9.28 | -5.45 |
EBT Excluding Unusual Items | -103.94 | -84.54 | -453.77 | -309.68 | -255.04 | -127.89 |
Impairment of Goodwill | -5 | -5 | - | - | - | - |
Gain (Loss) on Sale of Investments | -0.35 | -0.43 | -109.7 | -25.28 | - | -4.9 |
Gain (Loss) on Sale of Assets | 25.74 | -0.67 | 0.99 | 47.44 | 8.81 | 0.13 |
Asset Writedown | -23.73 | -2.92 | -14.97 | -1.4 | -0.41 | -33.66 |
Other Unusual Items | 2.23 | 2.23 | -3.85 | 9.78 | 10.94 | 3.56 |
Pretax Income | -100.88 | -87.16 | -578.58 | -278.22 | -235.7 | -160.76 |
Income Tax Expense | 2.57 | -0.32 | -12.69 | -42.51 | -15.14 | -2.17 |
Earnings From Continuing Operations | -103.46 | -86.84 | -565.89 | -235.71 | -220.56 | -158.6 |
Minority Interest in Earnings | -11.9 | -20.51 | 104.25 | -43.7 | 5.82 | 1.15 |
Net Income | -115.36 | -107.36 | -461.64 | -279.41 | -214.74 | -157.45 |
Net Income to Common | -115.36 | -107.36 | -461.64 | -279.41 | -214.74 | -157.45 |
Shares Outstanding (Basic) | 290 | 290 | 290 | 242 | 266 | 242 |
Shares Outstanding (Diluted) | 290 | 290 | 290 | 242 | 266 | 242 |
Shares Change (YoY) | -0.04% | - | 19.99% | -9.09% | 9.99% | 0.00% |
EPS (Basic) | -0.40 | -0.37 | -1.59 | -1.16 | -0.81 | -0.65 |
EPS (Diluted) | -0.40 | -0.37 | -1.59 | -1.16 | -0.81 | -0.65 |
Free Cash Flow | 140.91 | 81.27 | -260.48 | 22.19 | -230.25 | -164.38 |
Free Cash Flow Per Share | 0.49 | 0.28 | -0.90 | 0.09 | -0.87 | -0.68 |
Gross Margin | 2.23% | 8.57% | -47.67% | 9.06% | 7.70% | 10.62% |
Operating Margin | -11.79% | -9.57% | -64.79% | -28.47% | -36.75% | -14.29% |
Profit Margin | -16.19% | -13.39% | -68.85% | -29.57% | -33.66% | -27.03% |
Free Cash Flow Margin | 19.77% | 10.14% | -38.85% | 2.35% | -36.09% | -28.22% |
EBITDA | -41.87 | -38.75 | -401.97 | -254.53 | -220.24 | -69.56 |
EBITDA Margin | -5.88% | -4.83% | -59.95% | -26.94% | -34.52% | -11.94% |
D&A For EBITDA | 42.15 | 37.98 | 32.41 | 14.52 | 14.27 | 13.71 |
EBIT | -84.01 | -76.72 | -434.38 | -269.05 | -234.52 | -83.27 |
EBIT Margin | -11.79% | -9.57% | -64.79% | -28.47% | -36.75% | -14.29% |
Revenue as Reported | 712.64 | 801.51 | 670.45 | 944.91 | 638.08 | - |
Advertising Expenses | - | 0.21 | 0.02 | 0.01 | 0.25 | 0.11 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.